NR 565 Final / Midterm EXAM:Advanced
Pharmacology | 100% Verified Actual Exam
Questions & Answers | Grade A -
Chamberlain
This comprehensive Chamberlain NR 565 study guide bundles verified actual questions,
answers, and detailed rationales for both the Midterm and Final exams. It features 100+ highly
relevant exam-style questions—including multiple-choice, SATA, and case-based scenarios—to
guarantee a solid passing score in Advanced Pharmacology.
Why Choose This Study Guide?
This resource is specifically tailored to Chamberlain University’s Advanced Pharmacology
curriculum to help you tackle your exams confidently.
• 100+ Actual Exam Questions: Includes exact and highly similar questions that
mirror the latest Chamberlain Midterm and Final test banks.
• Detailed Rationales: Every answer comes with a step-by-step clinical explanation,
helping you understand why the answer is correct rather than just memorizing it.
• High-Yield Clinical Scenarios: Features scenario-based questions that test your
ability to apply pharmacological principles to patient care, as noted by students
preparing for the course.
• Format Varieties: Includes multiple-choice questions (MCQs), Select All That Apply
(SATA), matching, and dosage calculations commonly found on the test.
What Topics Are Covered?
This bundle completely covers the core competency modules of NR 565, including:
Midterm Exam Focus
• Pharmacokinetics, pharmacodynamics, and prescription writing guidelines.
• Age-related pharmacological changes (pediatric and geriatric/BEERS criteria).
• Drug therapy during pregnancy and lactation.
• Autonomic nervous system, pain management, and CNS drugs.
Final Exam Focus
1
, • Antimicrobial stewardship and broad antibiotic classifications (e.g., penicillins,
cephalosporins, macrolides, fluoroquinolones).
• Antifungal and antiviral agents.
• Endocrine therapeutics, including nuanced insulin regimens, thyroid disorders, and
adrenal medications.
• Cardiovascular, pulmonary, and gastrointestinal agents.
Exam Specs & Delivery
• Format: Digital PDF Document (Instant Download)
• Version: Updated for the latest testing blueprints
• Condition: A+ Graded Quality / Verified
Q1. Which statement correctly describes metoprolol's role in hyperthyroidism
management? [Multiple Choice]
A) Metoprolol is contraindicated in patients with hyperthyroidism
B) Metoprolol can be used to treat tachycardia experienced with hyperthyroidism, but
it does not treat hyperthyroidism itself.
C) Metoprolol suppresses thyroid hormone synthesis
D) Metoprolol suppresses thyroid hormone release
Answer: Metoprolol can be used to treat tachycardia experienced with hyperthyroidism,
but it does not treat hyperthyroidism itself.
Explanation: Beta blockers like metoprolol control symptoms (tachycardia, tremor) by blocking
adrenergic effects but do not change thyroid hormone production or release. Drugs that suppress
synthesis (methimazole) or release (iodine) are used to treat the thyroid overactivity itself.
Metoprolol is not universally contraindicated in hyperthyroidism; it is commonly used for
symptomatic control unless specific contraindications exist.
Q2. How often should A1C be rechecked while attempting to lower it to goal,
and after goal is reached? [Multiple Choice]
A) Once a year regardless of control
B) Every 6 months until A1C drops below 7%, then annually
C) Every 3 months until A1C drops below 7%, then every 6 months thereafter
2
, D) Monthly until A1C drops below 7%, then every 3 months
Answer: Every 3 months until A1C drops below 7%, then every 6 months thereafter
Explanation: Frequent A1C monitoring (every 3 months) is used while adjusting therapy because
A1C reflects ~3 months of glycemia; once stable and below goal, spacing to every 6 months is
reasonable. Waiting 6 months initially delays adjustments; monthly testing is unnecessary
because A1C changes slowly; annual testing is inadequate for active management.
Q3. In the diagram, which combination of symptom frequency defines
intermittent asthma? [Multiple Choice]
A) Symptoms ≤ 2 days/week, nighttime awakenings ≤ 2 times/month, SABA use ≤ 2
days/week
B) Symptoms ≤ 2 days/week, nighttime awakenings ≤ 4 times/month, SABA use ≤ 7
days/week
C) Symptoms ≤ 2 days/month, nighttime awakenings ≤ 2 times/week, SABA use ≤ 2
days/month
D) Symptoms ≤ 7 days/week, nighttime awakenings ≤ 4 times/month, SABA use ≤ 4
days/week
Answer: Symptoms ≤ 2 days/week, nighttime awakenings ≤ 2 times/month, SABA use ≤ 2
days/week
Explanation: Intermittent asthma is characterized by infrequent symptoms: two or fewer days
per week, two or fewer nighttime awakenings per month, and SABA use two or fewer days per
week. The distractors either swap weekly/monthly frequencies, increase the allowed frequencies,
or mix up the timeframes and therefore do not match the definition of intermittent asthma.
Q4. Which combination best represents recommended treatments for thyroid
storm? [Multiple Choice]
A) High-dose potassium iodide (or strong iodine), methimazole, a beta blocker,
sedation, cooling, glucocorticoids, and IV fluids
B) Beta blocker, cooling, and IV fluids only
C) High-dose iodine and methimazole only
D) Methimazole and beta blocker only
Answer: High-dose potassium iodide (or strong iodine), methimazole, a beta blocker,
sedation, cooling, glucocorticoids, and IV fluids
3
, Explanation: Thyroid storm is an extreme, multisystem emergency requiring rapid suppression of
hormone release (iodine), inhibition of synthesis (methimazole), control of adrenergic effects
(beta blocker), and supportive measures (sedation, cooling, glucocorticoids, IV fluids). Using only
one or two interventions may not address the multiple pathways driving the crisis.
Q5. What is the general hemoglobin A1C goal for most patients, and when is a
less stringent goal acceptable? [Multiple Choice]
A) General goal < 6%; a goal < 7% for patients with complications
B) General goal < 7.5%; a goal < 9% for older adults
C) General goal < 7%; a goal < 8% may be used for patients with severe hypoglycemia,
limited life expectancy, or advanced vascular complications
D) General goal < 8% for all patients
Answer: General goal < 7%; a goal < 8% may be used for patients with severe
hypoglycemia, limited life expectancy, or advanced vascular complications
Explanation: A general A1C target of <7% balances glucose control and safety. Less strict targets
(e.g., <8%) are appropriate for patients at higher risk from tight control — those with severe
hypoglycemia history, limited life expectancy, or advanced microvascular/macrovascular disease.
Tighter or universally higher targets listed in the distractors do not match these individualized
recommendations.
Q6. In the diagram, which statement best describes how total daily insulin dose
(TDD) is divided between components? [Multiple Choice]
A) Basal insulin ≈ 50% of TDD and bolus insulin ≈ 50% of TDD
B) Basal insulin = 100% of TDD and bolus insulin = 0% of TDD
C) Basal insulin ≈ 30% of TDD and bolus insulin ≈ 70% of TDD
D) Basal insulin ≈ 70% of TDD and bolus insulin ≈ 30% of TDD
Answer: Basal insulin ≈ 50% of TDD and bolus insulin ≈ 50% of TDD
Explanation: Total daily insulin is typically split evenly: about half replaces basal requirements
(overnight and between meals) and half is given as bolus (mealtime) insulin. The other splits
listed (70/30, 30/70, or 100/0) do not represent the standard approximation used for basal/bolus
planning.
Q7. Which formulas are used to calculate the carbohydrate-to-insulin ratio and
estimate the total daily dose (TDD) of insulin? [Multiple Choice]
A) Carbohydrate-to-insulin ratio = 500 ÷ body weight; estimated TDD = 0.6 units/kg/day
4
Pharmacology | 100% Verified Actual Exam
Questions & Answers | Grade A -
Chamberlain
This comprehensive Chamberlain NR 565 study guide bundles verified actual questions,
answers, and detailed rationales for both the Midterm and Final exams. It features 100+ highly
relevant exam-style questions—including multiple-choice, SATA, and case-based scenarios—to
guarantee a solid passing score in Advanced Pharmacology.
Why Choose This Study Guide?
This resource is specifically tailored to Chamberlain University’s Advanced Pharmacology
curriculum to help you tackle your exams confidently.
• 100+ Actual Exam Questions: Includes exact and highly similar questions that
mirror the latest Chamberlain Midterm and Final test banks.
• Detailed Rationales: Every answer comes with a step-by-step clinical explanation,
helping you understand why the answer is correct rather than just memorizing it.
• High-Yield Clinical Scenarios: Features scenario-based questions that test your
ability to apply pharmacological principles to patient care, as noted by students
preparing for the course.
• Format Varieties: Includes multiple-choice questions (MCQs), Select All That Apply
(SATA), matching, and dosage calculations commonly found on the test.
What Topics Are Covered?
This bundle completely covers the core competency modules of NR 565, including:
Midterm Exam Focus
• Pharmacokinetics, pharmacodynamics, and prescription writing guidelines.
• Age-related pharmacological changes (pediatric and geriatric/BEERS criteria).
• Drug therapy during pregnancy and lactation.
• Autonomic nervous system, pain management, and CNS drugs.
Final Exam Focus
1
, • Antimicrobial stewardship and broad antibiotic classifications (e.g., penicillins,
cephalosporins, macrolides, fluoroquinolones).
• Antifungal and antiviral agents.
• Endocrine therapeutics, including nuanced insulin regimens, thyroid disorders, and
adrenal medications.
• Cardiovascular, pulmonary, and gastrointestinal agents.
Exam Specs & Delivery
• Format: Digital PDF Document (Instant Download)
• Version: Updated for the latest testing blueprints
• Condition: A+ Graded Quality / Verified
Q1. Which statement correctly describes metoprolol's role in hyperthyroidism
management? [Multiple Choice]
A) Metoprolol is contraindicated in patients with hyperthyroidism
B) Metoprolol can be used to treat tachycardia experienced with hyperthyroidism, but
it does not treat hyperthyroidism itself.
C) Metoprolol suppresses thyroid hormone synthesis
D) Metoprolol suppresses thyroid hormone release
Answer: Metoprolol can be used to treat tachycardia experienced with hyperthyroidism,
but it does not treat hyperthyroidism itself.
Explanation: Beta blockers like metoprolol control symptoms (tachycardia, tremor) by blocking
adrenergic effects but do not change thyroid hormone production or release. Drugs that suppress
synthesis (methimazole) or release (iodine) are used to treat the thyroid overactivity itself.
Metoprolol is not universally contraindicated in hyperthyroidism; it is commonly used for
symptomatic control unless specific contraindications exist.
Q2. How often should A1C be rechecked while attempting to lower it to goal,
and after goal is reached? [Multiple Choice]
A) Once a year regardless of control
B) Every 6 months until A1C drops below 7%, then annually
C) Every 3 months until A1C drops below 7%, then every 6 months thereafter
2
, D) Monthly until A1C drops below 7%, then every 3 months
Answer: Every 3 months until A1C drops below 7%, then every 6 months thereafter
Explanation: Frequent A1C monitoring (every 3 months) is used while adjusting therapy because
A1C reflects ~3 months of glycemia; once stable and below goal, spacing to every 6 months is
reasonable. Waiting 6 months initially delays adjustments; monthly testing is unnecessary
because A1C changes slowly; annual testing is inadequate for active management.
Q3. In the diagram, which combination of symptom frequency defines
intermittent asthma? [Multiple Choice]
A) Symptoms ≤ 2 days/week, nighttime awakenings ≤ 2 times/month, SABA use ≤ 2
days/week
B) Symptoms ≤ 2 days/week, nighttime awakenings ≤ 4 times/month, SABA use ≤ 7
days/week
C) Symptoms ≤ 2 days/month, nighttime awakenings ≤ 2 times/week, SABA use ≤ 2
days/month
D) Symptoms ≤ 7 days/week, nighttime awakenings ≤ 4 times/month, SABA use ≤ 4
days/week
Answer: Symptoms ≤ 2 days/week, nighttime awakenings ≤ 2 times/month, SABA use ≤ 2
days/week
Explanation: Intermittent asthma is characterized by infrequent symptoms: two or fewer days
per week, two or fewer nighttime awakenings per month, and SABA use two or fewer days per
week. The distractors either swap weekly/monthly frequencies, increase the allowed frequencies,
or mix up the timeframes and therefore do not match the definition of intermittent asthma.
Q4. Which combination best represents recommended treatments for thyroid
storm? [Multiple Choice]
A) High-dose potassium iodide (or strong iodine), methimazole, a beta blocker,
sedation, cooling, glucocorticoids, and IV fluids
B) Beta blocker, cooling, and IV fluids only
C) High-dose iodine and methimazole only
D) Methimazole and beta blocker only
Answer: High-dose potassium iodide (or strong iodine), methimazole, a beta blocker,
sedation, cooling, glucocorticoids, and IV fluids
3
, Explanation: Thyroid storm is an extreme, multisystem emergency requiring rapid suppression of
hormone release (iodine), inhibition of synthesis (methimazole), control of adrenergic effects
(beta blocker), and supportive measures (sedation, cooling, glucocorticoids, IV fluids). Using only
one or two interventions may not address the multiple pathways driving the crisis.
Q5. What is the general hemoglobin A1C goal for most patients, and when is a
less stringent goal acceptable? [Multiple Choice]
A) General goal < 6%; a goal < 7% for patients with complications
B) General goal < 7.5%; a goal < 9% for older adults
C) General goal < 7%; a goal < 8% may be used for patients with severe hypoglycemia,
limited life expectancy, or advanced vascular complications
D) General goal < 8% for all patients
Answer: General goal < 7%; a goal < 8% may be used for patients with severe
hypoglycemia, limited life expectancy, or advanced vascular complications
Explanation: A general A1C target of <7% balances glucose control and safety. Less strict targets
(e.g., <8%) are appropriate for patients at higher risk from tight control — those with severe
hypoglycemia history, limited life expectancy, or advanced microvascular/macrovascular disease.
Tighter or universally higher targets listed in the distractors do not match these individualized
recommendations.
Q6. In the diagram, which statement best describes how total daily insulin dose
(TDD) is divided between components? [Multiple Choice]
A) Basal insulin ≈ 50% of TDD and bolus insulin ≈ 50% of TDD
B) Basal insulin = 100% of TDD and bolus insulin = 0% of TDD
C) Basal insulin ≈ 30% of TDD and bolus insulin ≈ 70% of TDD
D) Basal insulin ≈ 70% of TDD and bolus insulin ≈ 30% of TDD
Answer: Basal insulin ≈ 50% of TDD and bolus insulin ≈ 50% of TDD
Explanation: Total daily insulin is typically split evenly: about half replaces basal requirements
(overnight and between meals) and half is given as bolus (mealtime) insulin. The other splits
listed (70/30, 30/70, or 100/0) do not represent the standard approximation used for basal/bolus
planning.
Q7. Which formulas are used to calculate the carbohydrate-to-insulin ratio and
estimate the total daily dose (TDD) of insulin? [Multiple Choice]
A) Carbohydrate-to-insulin ratio = 500 ÷ body weight; estimated TDD = 0.6 units/kg/day
4
